Acromegaly - 140 Studies Found Suspended : Pharmacodynamics Of Product Octreotide Acetate Lar 30 Mg, Imported And Distributed By The Laboratory Chemical Pharmaceutical Bergamo Ltda., Compared To Product Sandostatin LAR ® (Octreotide Acetate LAR) 30 MG Manufactured By Novartis Biosciences S / A. : Acromegaly : 2010-03-12 : Drug: Octreotide acetate LAR 3 Completed : Non Interventional Study For Patients Treated With Somavert® : Acromegaly : 2009-03-06 : Other: Non Interventional Observation Post marketing surveillance study = prospective, non-interventiona Completed : Study to Assess the Efficacy of an Extended Injection Interval Schedule of Lanreotide Autogel in Acromegalic Subjects : Acromegaly : 2008-06-18 : Drug: Lanreotide Autogel 120 mg 120mg, injections every 6 weeks, then depending on IGF-1 results at Week Completed : Lanreotide as Primary Treatment for Acromegalic Patients With Pituitary Gland Macroadenoma : Acromegaly : 2008-06-03 : Drug: Lanreotide autogel 120 mg 12 months Completed : Long Term Use of Pegvisomant For A Regulatory Post Marketing Commitment Plan : Acromegaly : 2008-04-09 : Drug: Pegvisomant Pegvisomant 10, 15 or 20mg powder and so Completed : Predictive Factors of Response to Somatostatin Analogues in Acromegalic Patients With Persistent Disease Following Surgery : Acromegaly : 2007-07-11 Completed : Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients : Acromegaly : 2006-10-02 : Drug: lanreotide (Autogel formulation) Completed : Estrogen Treatment in Acromegalic Women : Acromegaly : 2006-04-13 : Drug: Alesse Completed : Efficacy and Safety of Lanreotide Autogel (60, 90 or 120 mg) in Acromegalic Patients : Acromegaly : 2005-09-19 : Drug: Lanreotide (Autogel formulation) Completed : Canadian Pegvisomant Compassionate Study In Acromegalic Patients : Acromegaly : 2005-09-07 : Drug: Pegvisomant treatment Procedure: Med <<< Previous | Next >>>
